Skip to main content

Asparaginase erwinia chrysanthemi (recombinant)- rywn

Details of the Drug
Generic Name:
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Drug Type:
Asparagine specific enzyme
How the Drug is Given:

Injection, for intramuscular use

Asparaginase erwinia chrysanthemi (recombinant)- rywn

Indications and Usage

Rylaze™ is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. 

Side effects needing medical attention

The most common adverse reactions are abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, fever, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.